These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. LC‑MS/MS metabolome analysis detects the changes in the lipid metabolic profiles of dMMR and pMMR cells. Peng W; Tan S; Xu Y; Wang L; Qiu D; Cheng C; Lin Y; Liu C; Li Z; Li Y; Zhao Y; Li Q Oncol Rep; 2018 Aug; 40(2):1026-1034. PubMed ID: 29989648 [TBL] [Abstract][Full Text] [Related]
4. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers. Hale VL; Jeraldo P; Chen J; Mundy M; Yao J; Priya S; Keeney G; Lyke K; Ridlon J; White BA; French AJ; Thibodeau SN; Diener C; Resendis-Antonio O; Gransee J; Dutta T; Petterson XM; Sung J; Blekhman R; Boardman L; Larson D; Nelson H; Chia N Genome Med; 2018 Oct; 10(1):78. PubMed ID: 30376889 [TBL] [Abstract][Full Text] [Related]
5. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774 [TBL] [Abstract][Full Text] [Related]
6. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients. Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296 [TBL] [Abstract][Full Text] [Related]
7. Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers. Li J; Guo Y; Liu J; Guo F; Du L; Yang Y; Li X; Ma Y J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597851 [TBL] [Abstract][Full Text] [Related]
8. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565 [TBL] [Abstract][Full Text] [Related]
9. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813 [TBL] [Abstract][Full Text] [Related]
10. Tumor Budding Karlberg M; Stenstedt K; Hallström M; Ragnhammar P; Lenander C; Edler D Anticancer Res; 2018 Aug; 38(8):4713-4721. PubMed ID: 30061240 [TBL] [Abstract][Full Text] [Related]
11. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167 [TBL] [Abstract][Full Text] [Related]
12. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria. Sun CY; Chiang JM; Chen TC; Hung HY; You JF World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993 [TBL] [Abstract][Full Text] [Related]
13. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors. Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347 [TBL] [Abstract][Full Text] [Related]
14. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair. Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788 [TBL] [Abstract][Full Text] [Related]
15. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer. Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323 [TBL] [Abstract][Full Text] [Related]
16. Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy? Chen M; Liu H; Liang W; Huang P; Ye F; Cai Y; Liang Z; Xiong L; Kang L; Huang L Br J Cancer; 2024 Mar; 130(5):798-807. PubMed ID: 38218920 [TBL] [Abstract][Full Text] [Related]
17. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell. Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974 [TBL] [Abstract][Full Text] [Related]
18. Application of immune checkpoint inhibitors in colorectal cancer. Wang L; Huang C Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736 [TBL] [Abstract][Full Text] [Related]
19. The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy. Halldorsson MO; Hauptmann M; Snaebjornsson P; Haraldsdóttir KH; Aspelund T; Gudmundsson EF; Gudnason V; Jonasson JG; Haraldsdottir S Scand J Gastroenterol; 2018 Aug; 53(8):972-975. PubMed ID: 30010450 [TBL] [Abstract][Full Text] [Related]
20. [Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers]. Chen K; Liang H; Peng J; Zheng Y Nan Fang Yi Ke Da Xue Xue Bao; 2018 Nov; 38(11):1300-1305. PubMed ID: 30514676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]